CDiddy, Leronlimab blocks ccr5, blocking immune
Post# of 148168
(Total Views: 532)
Posted On: 01/26/2022 2:07:10 PM
CDiddy,
Leronlimab blocks ccr5, blocking immune hyperactivation which persists in Omicron or we would it be witnessing 2,000+ deaths daily in the US.
Covid, influenza, Ebola all follow similar pathways, addressable by Leronlimab. The symptoms may vary, but the underlying immune activation shares a common pathway.
Covid is the first acute infection addressed by Leronlimab. It won’t be the last.
Leronlimab blocks ccr5, blocking immune hyperactivation which persists in Omicron or we would it be witnessing 2,000+ deaths daily in the US.
Covid, influenza, Ebola all follow similar pathways, addressable by Leronlimab. The symptoms may vary, but the underlying immune activation shares a common pathway.
Covid is the first acute infection addressed by Leronlimab. It won’t be the last.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼